Prescription Drug Recall: Enalapril Maleate Due to Manufacturing Deviations
Golden State Medical Supply Inc. is recalling 1,424 bottles of Enalapril Maleate 20 mg tablets due to Current Good Manufacturing Practice deviations. The affected lot numbers have expiration dates ranging from March 2022 to December 2022.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II voluntary precautionary recall for manufacturing compliance deviations with no reported illnesses or injuries. The hazard is theoretical, fitting the rubric criterion for 'voluntary precautionary recalls' at severity score 2.
Plain-English summary
Golden State Medical Supply Inc. is recalling Enalapril Maleate Tablets, USP 20 mg, distributed nationwide to customers in Pennsylvania, Massachusetts, Ohio, Texas, Illinois, North Dakota, and Hawaii. Approximately 1,424 bottles with NDC 60429-186-90 are affected, manufactured by Taro Pharmaceutical Industries, Ltd.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations identified during manufacturing. This voluntary recall was initiated by the firm on March 16, 2022, and the FDA classified it as a Class II recall on July 7, 2022.
The affected lot numbers and expiration dates are: GS035031 and GS035199 (expires 03/2022), GS036495 and GS036904 (expires 05/2022), GS037401 (expires 09/2022), GS037986, GS038359, and GS039560 (expires 11/2022), and GS041110 (expires 12/2022).
No illnesses or injuries have been reported in connection with this recall. The recall status remains ongoing.
The recalled product
- Product
- ENALAPRIL MALEATE (ENALAPRIL MALEATE)
- Brand
- ENALAPRIL MALEATE
- Manufacturer
- Golden State Medical Supply Inc.
- Category
- Drug
- Hazard
- Affected units
- 1,424
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (16)
- Lots: GS035031
- GS035199
- 20 mg
- 90 tablets
- Exp.: 03/2022
- Lots: GS036495
- GS036904
- Exp.: 05/2022
- Lots: GS037401
- Exp.: 09/2022
- Lots: GS037986
- GS038359
- GS039560
- Exp.: 11/2022
- Lot: GS041110
- Exp.: 12/2022. (NDC: 60429-186-90).
Distribution
Part of a larger recall action
This product is one of 4 recalled by Golden State Medical Supply Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same brand · ENALAPRIL MALEATE
- ModerateEnalapril Maleate 20 mg tablets recalled for out-of-specification impurities
FDA (Drugs) · 2026-05-13
- ModerateFDA Recalls Enalapril Maleate Tablets Over Manufacturing Practice Deviations
FDA (Drugs) · 2022-07-13
- ModerateEnalapril Maleate Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2022-07-13
- ModeratePrescription drug Enalapril Maleate recalled for manufacturing deviations
FDA (Drugs) · 2022-07-13
Same manufacturer · Golden State Medical Supply Inc.
See all →- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- HighBaclofen tablet bottles recalled over the presence of foreign tablets
FDA (Drugs) · 2025-12-24
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19